Home > Publications Database > Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice > print

001     272592
005     20250127091449.0
024 7 _ |a pmid:39409066
|2 pmid
024 7 _ |a 10.3390/ijms251910737
|2 doi
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
024 7 _ |a pmc:PMC11476365
|2 pmc
037 _ _ |a DZNE-2024-01213
082 _ _ |a 540
100 1 _ |a Fischer, Thomas
|0 P:(DE-2719)9000370
|b 0
245 _ _ |a Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice
260 _ _ |a Basel
|c 2024
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1729175535_2185
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Preliminary studies on a radioactive antibody against the neural cell adhesion molecule (NCAM) demonstrated a significant accumulation of [131I]I-ERIC1 in neuroblastoma tumor cells in mice. This study aims to validate the therapeutic efficacy and potential adverse effects of these radioactive immunoconjugates (RICs) in neuroblastoma-bearing mice. To determine the highest tolerated dose, healthy SCID mice received 1 to 22 MBq of [131I]I-ERIC1, with the survival time measured. Tumor response was evaluated by administering 0.8 to 22 MBq of [131I]I-ERIC1 to neuroblastoma-bearing mice and assessing tumor size and systemic toxicity through body weight, blood counts, and survival. It was observed that doses up to approximately 3 MBq per animal (150 MBq/kg) were well tolerated, whereas higher doses resulted in systemic toxicity and death. The neuroblastomas exhibited a dose-dependent response, with optimal therapeutic efficacy achieved at 1.8-2.5 MBq per animal (90-125 MBq/kg), significantly extending survival by a factor of five. The antibody ERIC1 is a promising vehicle for the transport of beta emitters into NCAM-positive tumor tissue. An optimal dosage of the [131I]I-ERIC1 antibody can be established with a balance of tumor-static effects and adverse effects, resulting in a marked extension of survival time.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Neuroblastoma: pathology
|2 MeSH
650 _ 2 |a Neuroblastoma: metabolism
|2 MeSH
650 _ 2 |a Neuroblastoma: drug therapy
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Iodine Radioisotopes: adverse effects
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Neural Cell Adhesion Molecules: metabolism
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mice, SCID
|2 MeSH
650 _ 2 |a Xenograft Model Antitumor Assays
|2 MeSH
650 _ 2 |a Immunoconjugates: pharmacology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal: pharmacology
|2 MeSH
700 1 _ |a Dietlein, Felix
|0 0000-0002-6651-7155
|b 1
700 1 _ |a Bongartz, Detlev
|b 2
700 1 _ |a Klehr, Martin
|b 3
700 1 _ |a Zimmermanns, Beate
|0 0009-0009-2207-9657
|b 4
700 1 _ |a Schmidt, Matthias
|0 0000-0002-7519-8897
|b 5
700 1 _ |a Mohr, Angela
|b 6
700 1 _ |a Mohr, Fabian
|0 0000-0001-7272-935X
|b 7
700 1 _ |a Sudbrock, Ferdinand
|b 8
700 1 _ |a Krapf, Philipp
|b 9
700 1 _ |a Drzezga, Alexander
|0 P:(DE-2719)2811239
|b 10
|u dzne
700 1 _ |a Dietlein, Markus
|0 0000-0003-0992-6099
|b 11
700 1 _ |a Schomäcker, Klaus
|b 12
770 _ _ |a Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 3.0
773 _ _ |a 10.3390/ijms251910737
|g Vol. 25, no. 19, p. 10737 -
|0 PERI:(DE-600)2019364-6
|n 19
|p 10737
|t International journal of molecular sciences
|v 25
|y 2024
|x 1422-0067
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272592/files/DZNE-2024-01213.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272592/files/DZNE-2024-01213.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272592
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811239
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J MOL SCI : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-07-07T16:31:47Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-07-07T16:31:47Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011202
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21